Iovance Biotherapeutics (IOVA) reported a Q1 loss late Thursday of $0.36 per diluted share, narrower than a loss of $0.42 a year earlier.
Analysts polled by FactSet expected a loss of $0.24.
Revenue for the quarter ended March 31 was $49.3 million compared with $715,000 a year earlier.
Analysts surveyed by FactSet expected $82.4 million.
The company trimmed its 2025 product revenue guidance to $250 million to $300 million from $450 million to $475 million.
Iovance shares were down 36% in recent premarket activity Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.